ioSensory Neurons: Human iPSC-Derived Neurons for Reliable Pain Research
One of the biggest challenges in pain research is the lack of a physiologically relevant in vitro cell models with consistent nociceptor marker expression and functionality.
ioSensory Neurons are built to address this challenge. They are a highly pure, easy to use and functional human iPSC-derived nociceptor model. As the cells are precision reprogrammed with opti-ox™ technology, ioSensory Neurons have consistency built-in and always express the same key markers regardless of lot or vial. Such consistency, combined with an unprecedented over 99% purity, a validated functional nociceptor phenotype and a simple protocol will help chronic pain researchers to improve the reliability and reproducibility of their experiments.
Within 7 days post-revival, ioSensory Neurons form a highly pure sensory neuronal population with a defined nociceptor identity, characterised by the expression of the pan-sensory neuron markers, PRPH, BRN3A, ISL1 and TUBB3, and key markers of nociceptors, NTRK1 and TRPV1. These cells also display spontaneous activity and show a functional nociceptor phenotype, as demonstrated by responsiveness to noxious stimuli against TRPV1, TRPM3, and TRPM8.
Don’t settle for non-human in vitro models or long, complex iPSC differentiation protocols that lead to inconsistent results. Start running reliable nociception assays with ioSensory Neurons today.
ioSensory Neurons are now available under an early access program. Fill out the form to speak to an expert about ioSensory Neurons.
Quality controlterility, protein expression (ICC) and gene expression (RT-qPCR)
Vial size>2 x 10⁶ viable cells
Seeding compatibility6, 12, 24, 96 and 384 well plates
Recommended seeding density60,000 cells/cm²
Product useResearch use only
bit.bio is an award-winning human synthetic biology company based in Cambridge, UK.
Our cell identity coding platform has the ability to create any human cell type and to manufacture it at scale with precision and consistency. Having access to human cells has the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by human disease and form the basis for a new generation of cell and tissue therapies. It will enable us to realise our vision: biomedical innovation and a new generation of cures through precision reprogrammed human cells.
The cell identity coding platform consists of three core parts: our discovery platform which identifies the precise code that defines cell fate; our precision cellular reprogramming technology - opti-ox - that deterministically reprograms stem cells into any cell type; and our world leading expertise in stem cell reprogramming, manufacturing and clinical translation.
Using our platform, we have already launched multiple wild type and disease model cells under our ioCells™ brand for research and drug discovery. The platform also means we can offer custom partnership capabilities. And we are currently building our own, in-house cell therapy pipeline using our platform.